Cell Therapy News Volume 5.02 | Sep 12 2004

    0
    35
    Cell Therapy News 5.2, September 12, 2004
         In this issue: Science | Policy | Business | NIH | CBER | Regulatory
    Cell Therapy News on Facebook  Cell Therapy News on Twitter

    Top Stories

    Link: FDA Co-Sponsors Regulatory Cell Therapy Meeting in Houston, TX
    Article

    Link: FDA Announces Public Workshop on Facilitating Cellular Therapies as Part of Its Critical Path Initiative
    Article

    Science

    Stem Cell Discovery Could Aid In Diabetes Treatments
    A University of Alberta diabetes researcher has helped uncover a possible new source of insulin for diabetics and a valuable clue in the treatment of neurological disorders.
    Article

    Pancreatic stem cells can cure diabetes: Study
    Toronto University scientists have said that stem cells can be a cure for diabetes, thereby eradicating the need for replacing insulin. The experiments conducted on mice, the findings of which appear in the journal Nature Biotechnology, has revealed that immature cells in the pancreas of the mice upon treatment, could be developed into cells that produce insulin.  The scientists believe that their laboratory discovery will make it possible for them to generate new beta cells to cure insulin deficiency thereby making it possible to cure people afflicted with diabetes.
    story 1   story 2

    Israeli cell therapy tricks immune system into fighting cancer
    Forged by researchers at the Hadassah University Medical Center in Jerusalem, under the direction of Weisner Department of Bone Marrow Transplantation and Cancer Immunotherapy director and bone marrow transplantation pioneer Prof. Shimon Slavin, doctors have improved the science of training donor lymphocytes in a laboratory to act as honing devices to kill cancer cells, before being infused into a patient whose own lymphocytes are not properly doing their job.
    Article

    Blajchman MA et al. Proceedings of a consensus conference: the screening of blood donors for variant CJD. 
    Link

    Study Finds Immune Therapy for Metastic Breast Cancer Possible
    Article

    HIV-1 Nef equips dendritic cells to reduce survival and function of CD8+ T cells: a mechanism of immune evasion
    Article

    Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes
    Article

    Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia  
    article
     
    BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning 
    Article

    Photoimmune Therapy:  Expanded Applications for Graft-versus-Host Disease
    Link

    Stem Cell Research Foundation grant awards of up to $50,000 per year for two years 
    Application Deadline: Oct. 19, 2004
    Link

    Review Article Makes Case For A New Source Of Cells In The Body
    As the debate continues on the ethics and therapeutic potential of embryonic versus mature stem cells, Medical College of Georgia researchers are exploring a third group of cells that appears critical to development and capable of making all major types of human tissue.
    Article

    Discovery of potential stem cells could help those suffering from diabetes
    Article

    Scientists’ bioengineering feat
    Story

          The man who grew a new jaw on his back
          story 2

    Stem Cells Put Woman’s Arthritis in Remission
    Transplanting stem cells from a healthy woman to her sister with severe rheumatoid arthritis apparently cured the disease, researchers report in the journal Arthritis & Rheumatism.
    Story

    Stem cells: hope and setbacks (An Overview)
    At three laboratories in Boston, separated by a taxi ride of no more than 10 or 15 minutes, the world of stem cell research can be captured in all its complexity, promise and diversity.
    Article

    Stem cells Infusion Hoped to Halt Hearing Loss
    Timothy’s parents were told that their baby, who seemed so healthy, has Sandhoff disease, a degenerative, genetic illness that would steal his hearing, his ability to swallow and hold his head up on his own – and probably would kill him before his third birthday.  But a team at Duke in Durham, N.C., led by Dr. Joanne Kurtzberg, performed an experimental stem-cell transplant that they hope will halt the disease’s progression.
    Story

    Mice Stem Cells May Cure Human Deafness
    Story

    Heart ‘Repair Kit’ — Stem Cells Regenerate Injured Muscle
    Mayo Clinic researchers have demonstrated that stem cell therapy repairs damaged heart tissue and aids recovery after heart attack. The details of the animal-based study appear in the current issue of the American Journal of Physiology (Link

    ).
    article

    First Genetic Trust to Provide Tissue and Data Banking Systems for the Multiple Myeloma Research Consortium
    The Multiple Myeloma Research Consortium announced today that First Genetic Trust (FGT) has been selected as its technology partner to provide a comprehensive information technology infrastructure for managing its tissue and data banking needs. The system will be used to manage collaborative myeloma research programs across four leading academic medical research institutions that make up the MMRC’s Member Institutions (Link

    ) and associated research partners.
    Story

    Stem cells may help to minimise the effects of cerebral palsy
    According to researchers at the University College of Georgia natural chemicals that assist healing may one day help transplanted adult stem cells integrate into an injured brain, there by helping children with cerebral palsy to recover lost function.
    story 1  story 2

    TopAbstracts in Bone Marrow and PBSC Transplantation 08/12/2004 – (DGNews)
    Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma – (Bone Marrow Transplant)
    Probiotics in Relapsing and Chronic Diarrhea – (J Pediatr Hematol/Oncol)
    Low dose Thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma – (Blood)
    Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation – (Am J Clin Oncol)
    Bone metabolism in patients more than five years after bone marrow transplantation – (Bone Marrow Transplant)
    Link

    Cardiac Lymphoma Successfully Treated with High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation
    Article

    Cardiac Localization of Graft-Versus-Host Disease After Allogenic Bone Marrow Transplantation
    Article

    A DGReview of :”Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR“. Blood
    review

    Parkinsons gene therapy patient well after 1 year suggesting that the therapy is safe and effective
    Story

    First step in using gene therapy to treat glaucoma
    Story

    Silencing Human Gene Through New Science of Epigenetics
    For the first time, scientists have shown how the activity of a gene associated with normal human development, as well as the occurrence of cancer and several other diseases, is repressed epigenetically — by modifying not the DNA code of a gene, but instead the spool-like histone proteins around which DNA tightly wraps itself in the nucleus of cells in the body.
    Story

    U.K. Gene therapy trial for tumours
    Researchers have been given approval to carry out a large clinical trial of a new treatment for patients with an aggressive type of brain tumour.
    Story

    ‘Smart Gene Therapy’ Protects Against Damage From Heart Attack
    Early intervention with a novel kind of “smart gene therapy” might effectively prevent the organ damage commonly suffered by heart attack victims, suggests a new animal study by researchers at Brigham and Women’s Hospital in Boston and Duke University Medical Center. The therapy combines a therapeutic gene with a genetic “sensor” that recognizes and responds to the oxygen deprivation that follows the reduced blood flow, or ischemia, from coronary artery disease and heart attack.
    Article

    Progress in the Use of Adeno-Associated Viral Vectors for Gene Therapy
    Article

    Cytotherapy. Volume 6, Number 4 / August 2004 
      Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells
      Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells
      Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal
      A preliminary analysis of the balance between Th1 and Th2 cells after CD34+ cell-selected autologous PBSC transplantation
      Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine
      Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2×106 CD34+ cells/kg
      Development of a technology platform for large-scale clinical grade production of DC
      Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential
      Preservation of G-CSF mobilized whole blood in an automated closed hollow-fiber bioreactor system
    Link


     

    Policy

    Scientists disagree on stem cells
    Story

    Diabetes group backing stem cell research
    Story

    Singapore rules on cloning
    Parliament passes law banning reproductive cloning, but allowing stem cell work
    Story

    Stem Cell Focus: Japan O.K.s Therapeutic Cloning
    Story

    Britain to allow cloning of human embryos
    Story

    Gene therapy in China attracting Westerners
    Story

    Clone doctor took parents’ cash for experiments
    Story

    California to vote on $3 billion stem cell project
    Story

    California stem cell propoposition has slight lead in field poll
    Story

    U.S. Groups at odds over research
    What began as a way to seek cures for illnesses has become a heated, political debate on whether embryonic stem-cell research should be expanded.
    Story

    Bush’s Stem-Cell Policy. Three-Years Old and Still the Right Choice
    Story

    Laura Bush enters stem cell row
    story 1  story 2

    Edwards holds conference call about stem cell research

    Story

    Kerry ‘would lift stem cell ban’
    Story

    Stem-cell use debated
    Ron Reagan’s speech fuels hope, opposition
    Story


     

    Business

                                        Market Reports

    Malachite Management has joined forces with an established and reputable author to bring you a report outlining the very latest in the Cell Therapy industry.  “Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
    For more information and order information see:
    Report Summary
    Sample Chapter
    Table of Contents
    Order Form

    Malachite Management has joined forces with an established and reputable author to bring you a report outlining the very latest in the Gene Therapy industry.  “Gene Therapy – Technologies, Markets and Companies” is 560 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
    For more information and order information see:
    Report Summary
     Table of Contents  Vol. 1  Vol. 2
    Order Form

    Malachite Management Inc. has teamed up with an established publisher to bring you the latest reports in immunotherapeutic approaches to cancer.
    A Shift in Cancer Immunotherapy Stategies?
      Executive Summary
      Table of Contents 
    Future Perspectives in Cancer Immunotherapy
      Executive Summary
      Table of Contents
    Immunotherapy Reports Order Form

    Drug and Market Development Publications (D&MD) predicts that the cell therapy market will near $30 billion by 2010.  D&MD has recently published a Market Analysis Report called Cell Therapy: Technology, Markets & Opportunities.  This Report describes the strategies and technologies corporations are employing to capture their share of this growing market.  In addition, the Report answers many important questions, including what diseases will significantly benefit from current and future research, how regulatory and ethical hurdles will come into play, and which corporations are poised to win.  For more information, including a FREE copy of the complete Table of Contents and Executive Summary, and sample Report excerpts, send an email to cust.serv@drugandmarket.com or for more information online click here.

                                       Business News

    Cell Genesys Starts Cancer Trial
    Biotechnology company Cell Genesys Inc. said Wednesday that it launched a multi-center, early-stage trial of CG7870, a virus therapy for prostate cancer, that will be administered in combination with Taxotere chemotherapy.
    Article

    Gamida-Cell, a leader in the development of stem cell expansion products for the treatment of cancer and autoimmune diseases, as well as cardiac and pancreatic repair, has published f MS# 03229 – The Linear Polyamine Copper Chelator Tetraethylenepentamine Augments Long-Term Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells and Increases Their Engraftment Potential in NOD/SCID Mice in the June issue of Experimental Hematology.
    Article

    Raymond J. Tesi, M.D. Joins Cellerant Therapeutics to Head Clinical Development and Medical Affairs
    release

    Genzyme, Medtronic launch joint heart venture
    Medtronic and Genzyme have launched a joint venture to develop new treatments to rebuild muscles damaged by a heart attack. MG Biotherapeutics will use cultured cells to do the work, which could have significant benefits for patients suffering from congestive heart failure. The venture expects to launch Phase III clinical trials in early 2008. Genzyme already makes a treatment to rebuild cartilage in the knee, while Medtronic has extensive experience making and marketing devices for the heart.
    release

    IPO: French biotech cancels million dollar IPO
    French biotech Immuno-Designed Molecules has cancelled plans to launch an IPO worth $120 million.
    Article

    Human stem cell bank planned for South Africa
    Story

    StemCells, Inc. Granted U.S. Patent for Human Neural Stem Cell Compositions
    Article

    Edwards Lifesciences Initiates Clinical Trial for Therapy Designed to Grow New Blood Vessels
    Link

    Dynabeads Mouse CD3/CD28 T Cell Expander offers the first ready-to-use system to provide simultaneous signals to TCR/CD3 and CD28 for full activation and expansion of mouse T cells in culture. 
    release

    Prometic’s Lead Cancer Compound PBI-1402 Has Confirmed Activity On Red Blood Cell Progenitors 
    ProMetic Life Sciences Inc. announces that its scientists have confirmed evidence of PBI-1402’s positive effect on the formation of red blood cells in bone marrow. This proliferation is additive with the red blood cell (erythrocyte) growth factor erythropoietin as indicated by in vitro experiments on human bone marrow. This announcement confirms a potential use of the compound for anemia caused by chemotherapy and renal diseases. 
    Article

    Xcyte Therapies Appoints Lawrence A. Romel As VP of Clinical Operations and Project Management
    release

    Robert L. Kirkman, MD Appointed Chief Business Officer And Vice President Of Xcyte Therapies
    Link


     

    NIH


    NIH Guide for Grants and Contracts – Week Of September 3, 2004
    Link

    RFP Announcement: International Clinical Sciences Support – NIH-NIAID-DMID-05-07 (NOT-AI-04-053)
    National Institute of Allergy and Infectious Diseases
    Link

    QUICK-TRIALS FOR NOVEL CANCER THERAPIES: EXPLORATORY GRANTS (PAR-04-155)
    National Cancer Institute
    Application Receipt Date(s): Multiple dates, see announcement
    Link

    PILOT AND FEASIBILITY PROGRAM IN HEMATOLOGIC DISEASES (PA-04-144)
    National Institute of Diabetes and Digestive and Kidney Diseases
    APPLICATION RECEIPT DATE(S):  Multiple dates, see announcement
    Link

    NOVEL APPROACHES TO ENHANCE ANIMAL STEM CELL RESEARCH
    (PA-04-125)
    National Center for Research Resources, National Cancer Institute, National Eye Institute, National Heart, Lung and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse,
    APPLICATION RECEIPT DATE(S): Multiple dates, see announcement
    Link

    EXTRAMURAL LOAN REPAYMENT PROGRAM FOR CLINICAL RESEARCHERS
    Link

    EXTRAMURAL PEDIATRIC RESEARCH LOAN REPAYMENT PROGRAM
    Link


     

    CBER

    All new CBER information can be reached from the Whats New page at
    Link

    From Concept to Consumer: Center for Biologics Evaluation and Research (CBER) Working with Stakeholders on Scientific Opportunities for Facilitating Development of Vaccines, Blood and Blood Products, and Cellular, Tissue, and Gene Therapies – Public Workshop
    October 7, 2004. Gaithersburg, MD
    Link

    FDA to Establish New Cancer Office and Program
    Changes Designed to Improve Efficiency and Consistency of Cancer Product Reviews
    Link

    Q and A’s Concerning Establishment Registration and Listing for Human Cells, Tissues, and Cellular and Tissue-Based Products(HCT/Ps) – Update
    Link

    Guidance on Research Involving Coded Private Information or Biological Specimens
    Link

    Biological Response Modifiers Advisory Committee Mtg “Cellular Products for the Treatment of Cardiac Disease”
    Briefing Information – (HTM)   (PDF)
    Bibliography – (HTM)
    Slides –   March 18 –  March 19
    March 18-19, 2004 Summary Minutes – HTM

    Mayo Clinic Comments on Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products
    (HCT/Ps)
    Link

    Electronic IND Demo
    Link

    Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 – Update
    Link

     

    Regulatory


    Proposed Tissue Storage and Issuance Standards-applies to bone marrow, stem cells, cord blood and other products (JCAHO, Aug. 21)
    Link

    Navigating FDA Regulations for Human Cells and Tissues (BioProcess Int’l – September)
    Link

          RESOURCES

    ISCT’s Cell Therapy Legal & Regulatory Affairs Online Resources Center:
     Link

    The Rules Governing Medicinal Products in the European Union

    WHO Quality Assurance and Safety of Medicines (QSM)

    ISPE Regulatory Information (International regulatory agencies and documents)

    International Conference on Harmonisation (ICH) Guidances – Topics and Guidelines

    Code of Practice for the Production of Human-derived Therapeutic Products (UK)

    The 21CFRPart11.com Web site provides access to information on the rule and also maintains an email list that actively discusses issues and concerns with industry peers and government regulators.

    The FDA home page 
      Electronic FOI 
      The FDA dockets management homepage
      The FDA Modernization Act of 1997 (FDAMA) 
      Current Guidances 
     

          Regulatory Affairs Professionals Society
     RAPS 2004 Annual Conference & Exhibition. 10-13 October 2004. Washington, DC
     RAPS Combination Products Resource Page

    13-14 September 2004. Principles & Practices of US Regulatory Affairs.
    13-14 September 2004. Principles & Practices of EU Regulatory Affairs

         Other Regulatory Resources:
    Advanced Cell and Gene Therapy Consulting

    Biologics Regulatory Training Institute

    The Biologics Consulting Group


     

    Meetings

    Malachite’s Online Cell Therapy Conference Calendar
    For a more complete listing of conferneces, see Malachite Management’s new online, interactive Cell Therapy Calendar

    Other Online Conference Calendars
     by The BioMaterials Network 
     by The Pittsburgh Tissue Engineering Initiative
     by The Tissue Engineering Pages 
     by the American Society of Hematology
     by the International Society for Stem Cell Research
     
    Featured Conference
    NIH Symposium on Cardiovascular Regenerative Medicine
    September 13-14, 2004
    Natcher Conference Center, National Institutes of Health, Bethesda, Maryland
    This public workshop is designed to improve the development of biological products as part of the FDA’s “Critical Path” initiative. This symposium will focus on adult stem cell therapies for cardiovascular disease, highlighting both basic research and clinical applications.  Research experts involved in the basic science of stem cell biology, as well as clinical cardiovascular medicine experts, will discuss the emerging science, preclinical animal models, and the clinical applications to cardiovascular disease.  There will be an emphasis on the knowledge required to move basic science and preclinical work forward to clinical applications.  For more information and to register for the symposium, click here.  Registration is free.  If you have questions, please contact Judy Corbett, NHLBI, 31 Center Drive-MSC 2482, Room 5A06, Bethesda, MD 20892; phone: 301-496-4910; e-mail: corbettj@nhlbi.nih.gov.


            Conferences 2004

    Sept. 13-14  Symposium on Cardiovascular Regenerative Medicine.  NIH, Bethesda, MD. 

    September 21-22   Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues. Bethesda, MD. 

    Sept 15-27  Third International Symposium of Stem Cell.  Shenyang, China. 

    September 20-21  Cancer Immunotherapeutics.  Boston, MA. 

    September 26–30  USP’s Annual Scientific Meeting.  Iselin, NJ. 

    Sept. 30-Oct. 2.  Ninth Biennial National Symposium on Hematopoietic Cell Transplantation. Stanford, CA. 

    October 1-3  4th Annual Somatic Cell Therapy Symposium. Houston,Texas.

    Oct. 1-6  American Society for Histocompatibility and Immunogenetics (ASHI) 30th Annual Meeting.  San Antonio, TX. 

    October 3-7 Cell & Tissue BioProcessing Conference.  Houston, Texas. 

    October 4-7  BioProcess International(tm) Conference & Exhibition.  Boston, MA.

    October 10-13  RAPS 2004 Annual Conference & Exhibition. Washington, DC.

    October 13 – 16 13th International Conference of the European Association of Tissue Banks. Prague/Czech Republic.

    Oct. 14-16  4th Annual Mesencnymal & Nonhematopoietic Stem Cells Conference. New Orleans, LA. 

    Oct. 18-19  Stem Cells & Regenerative Medicine. Princeton, NJ. http://www.srinstitute.com/cs309

    October 23-26 Amer. Assoc. of Blood Banks Annual Meeting – Baltimore, Maryland.

    Oct. 21-25.  International Cytokine Society (ICS) and International Society for Interferon and Cytokine Research (ISICR) “Cytokines in Cancer and Immunity“. San Juan, Puerto Rico. 

    Oct. 26-30  American Society of Human Genetics (ASHG) 54th Annual Meeting. Toronto, Canada. 

    November 3-6  4th Annual Stem Cell Network Annual General Meeting, Montreal, Canada. 

    Nov. 4-7.  European Society of Gene Therapy (ESGT) 12th Annual Meeting. Tampere, Finland. 

    November 17-20 7th International congress of the Cell Transplant Society.  Boston, MA. 

    November 18-19  Commercialisation of Tissue Engineering and Regenerative Medicine. London, UK.

    November 19 – 21   2004 Hanson Symposium “Stem Cells: From Biology to Therapy”.  Adelaide, South Australia. 

    Nov. 22-24  2nd National Stem Cell Centre Annual Scientific Conference.  Sydney, Australia. 

    Dec. 4-8.  American Society for Cell Biology (ASCB) 44th Annual Meeting. Washington, D.C.

    December 9-10. DIA/EMEA Workshop on Gene Therapy & Cell Therapy Products.  London, UK. 

    December 3-7  Amer. Society for Hematology: 46h Annual Mtg – San Diego, California – San Diego, CA


                       Courses
    GEN Virtual Seminar Functional Orthopedic Tissue Engineering. Wednesday, September 29, 2004.   12:00 pm- 1:30 pm E.D.T. (NY Time). Link

    StemSoft Software Inc. is pleased to offer two days of hands-on training in conjunction with the IBMTR Data Manager’s Conference in Milwaukee, WI Sept. 20-21, 2004. This year StemSoft is pleased to offer classes on our BMTbase electronic IBMTR registry reporting software and our BMTstats statistical analyses application.  Link

    cGMP in the Transfusion Service. An online training course. Link

    NIH and other stem stem cell training courses – link

    Combination Products: Navigate Your Way to FDA Approval . A live, interactive audio alert
    Tuesday, Sept. 21, 2004 l 1:30 p.m. – 3:00 p.m. EDT.  Link

    Weekly – UCSFs Human Embryonic Stem Cell Training Program (3-day training course).  Link


                         Conferences 2005
    January 24-26  Phacilitate Cell & Gene Therapy Forum.  Washington DC

    Feb. 10-14 Tandem BMT Meetings (Combined ASBMT and IBMTR/ABMTR annual meetings).  Keystone, Colo. 

    March 16-20  American Society of Transplantation (AST) and Canadian Society of Transplantation (CST) Annual Winter Symposium. Banff, Canada.

    March 20–23  European Group for Blood & Marrow Transplantion Annual Mtg.  Prague, Czech Republic.

    May 18-20  2nd World Congress on Regenerative Medicine.  Leipzig, Germany. 

    May 3-7.  11th Annual Meeting and Scientific Conference of the International Society for Cellular Therapy (ISCT) Vancouver, Canada.  (combined with Good Tissue Practices Workshop & Flow Cytometry for HSC Transplantation Workshop)

    June 1-5  American Society of Gene Therapy Annual Meeting.  Saint Louis, MO. 

    June 23-25  3rd Annual Meeting of the International Society for Stem Cell Research. San Francisco, CA. 

    Sept 21-25  International Society of Pediatric Oncology Conference.  Vancouver, Canada. 

    Sept/Oct  Second International Epithelial Mesenchymal Transfer Conference.  Vancouver, Canada. 

    ISCT

    International Society for Cellular Therapy – www.celltherapy.org

    ISCT’s Quality Assurance Group launches online discussion board to discuss Quality Management issues via open, honest discussion by experienced, interested parties.


    Upcoming meetings include:

       4th Annual Somatic Cell Therapy Symposium (to be held in conjunction with the WilBio Cell & Tissue BioProcessing Conference).  October 1-3, 2004.  Houston, Texas.

       4th Annual Mesenchymal & Nonhematopoietic Stem Cells Conference. Oct. 14-16.  New Orleans, LA. 

     

    Profiled Journal

    Read Cytotherapy in 2005.  Join ISCT ($130) and receive the journal as a benefit of membership.

    Cytotherapy. Volume 6, Number 4 / August 2004 
      Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells
      Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells
      Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal
      A preliminary analysis of the balance between Th1 and Th2 cells after CD34+ cell-selected autologous PBSC transplantation
      Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine
      Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2×106 CD34+ cells/kg
      Development of a technology platform for large-scale clinical grade production of DC
      Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential
      Preservation of G-CSF mobilized whole blood in an automated closed hollow-fiber bioreactor system
    Link

     

    Cytotherapy publishes original research, reviews, meeting reports, special focus issues and letters in the general field of cell therapy. The scope of the journal includes includes basic and applied research with hematopoietic and non-hematopoietic stem cells , immune cells, and antigen-presenting cells. Therapeutic topics within the scope of Cytotherapy include ex-vivo and in-vivo aspects of gene therapy, immunotherapy, stem cell transplantation and tissue regeneration. Cytotherapy particularly welcomes
    contributions from researchers, clinicians, technicians and individuals involved in regulatory aspects of cell therapy.
    www.cytotherapy.com


     Learn more about Cell Therapy News:  Archives  |  Events  |  Update Profile  |  Contact Us